If you or a family member have cutaneous lupus erythematosus (CLE) and/or systemic lupus erythematosus (SLE), you may want to consider the LILAC clinical research study.
What is the purpose of the LILAC study?
The purpose of the LILAC study is to learn if an investigational medication may effectively reduce lupus skin activity in patients with CLE and/or SLE.
What is the investigational medication?
The investigational medication, BIIB059, is a monoclonal antibody administered as a subcutaneous injection. Antibodies are designed to recognize and attach to specific molecules in your body. BIIB059 attaches to the surface of a specific type of cell that is part of the immune system. When BIIB059 attaches to the immune system cells, it limits the production of certain protein, called IFNα, which may be associated with CLE and SLE symptoms.
Who can participate in the LILAC study?
You may be able to participate in this study if you:
How long is the study?
- Are 18 to 75 years old
- Have been diagnosed with CLE and/or SLE
- Have active lupus skin disease
If you are eligible for the study, your participation may last 28 to 40 weeks and include up to 13 visits to the study site.